A novel human papillomavirus (HPV) vaccine, manufactured using Escherichia coli, demonstrates strong protection against cancer-causing HPV strains in women. This finding, detailed in a recent study published in The Lancet Infectious Diseases, holds significant promise for expanding global access to HPV immunization, particularly in low- and middle-income countries, due to its lower production cost compared to existing vaccines.
Researchers, led by the Jiangsu Provincial Academy of Preventative Medicine in China, highlighted the vaccine’s potential to enhance global access to high-valency HPV vaccination programs.
Effective Defense Against High-Risk HPV Strains
Cervical cancer, largely caused by HPV, is the fifth most common cancer affecting women globally. In 2024, an estimated 604,000 women were diagnosed with cervical cancer, and sadly, 280,000 succumbed to the disease. The World Health Organization (WHO) notes that a disproportionate number of these fatalities occur in less affluent nations.
The WHO has set an ambitious goal to eliminate cervical cancer by achieving 90% vaccination coverage for girls worldwide by 2030. However, the considerable expense of current vaccines poses a significant hurdle for many countries aiming to implement comprehensive HPV immunization strategies.
To assess the protective capabilities of the E coli-produced nine-valent (9vHPV) HPV vaccine against HPV infection, investigators conducted a multicenter, double-blind, randomized clinical trial involving 9,327 unvaccinated women in China. The trial allocated 4,664 participants to receive the 9vHPV vaccine (Cecolin 9), while the remaining 4,663 received the two-valent HPV vaccine (Cecolin) as a control.
The study revealed that Cecolin 9 exhibited 98.2% efficacy in preventing persistent infection for one year against several high-risk HPV strains, including types 31, 33, 45, 52, and 58.
Experts Punnee Pitisuttihum, PhD, from Mahidol University in Thailand, and Rakesh Aggarwal, MD, DM, from Mahatma Gandhi University of Medical Science and Technology in India, commented in an accompanying editorial that the efficacy results of Cecolin 9 against 12-month persistent infection represent a crucial advancement. They also pointed out that the next critical steps involve securing licensing for the product beyond China and pursuing WHO prequalification to ensure Cecolin 9 adheres to international safety standards.